Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | CALML3 | P27482 | 1/20 | 0.34 |
| ▸ | SDHA | P31040 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5999433 | 0.96 | MAOA (0.38) | MAOAHSD11B1KMT2AMAOBLMNA | |
| SCHEMBL5999423 | 0.96 | MAOA (0.38) | MAOAHSD11B1KMT2AMAOBLMNA | |
| SCHEMBL5998076 | 0.88 | MAOA (0.39) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5999673 | 0.87 | MAOA (0.52) | MAOAHSD11B1MAOBHTR6F10 | |
| SCHEMBL5998091 | 0.86 | F10 (0.41) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5998591 | 0.84 | MAOA (0.38) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5503015 | 0.83 | BRD4 (0.41) | MAOAKMT2AMAOBLMNAPTGS1 | |
| SCHEMBL5998454 | 0.83 | MAOA (0.37) | MAOAKMT2AMAOBLMNAPTGS1 | |
| SCHEMBL5509015 | 0.83 | MAOA (0.37) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5509010 | 0.83 | MAOA (0.37) | MAOAMAOBLMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781642-A1 | OXAZOLIDINONES CONTAINING OXINDOLES AS ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company LLC (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006016221-A1 | OXAZOLIDINONES CONTAINING OXINDOLES AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060030609-A1 | Oxazolidinones containing oxindoles as antibacterial agents | LUEHR GARY W | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030609-A1 | Oxazolidinones containing oxindoles as antibacterial agents | OXA1L, OXSR1, OXER1 | MAOA 766/4885HSD11B1 993/4885KMT2A 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.